| Through new drug launches, panel discussions, and similar forums. | Patient advocacy
> Drugs and related treatments | Regulatory partnership
> Working with regulatory bodies | 1,000 | Regional | Sometimes | 115028447628 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | Cancer
> Cancer: most types | Regulatory partnership
> Participate in Health Technology Assessment (HTA) and reimbursement reviews | 10,000 | National | Regularly | 114998266569 |
| We assess cost-effectiveness. | Liver
> Liver diseases: most types | Regulatory partnership
> Participate in Health Technology Assessment (HTA) and reimbursement reviews | 100,000 | National | Sometimes | 114998327089 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | General health
> Healthcare delivery | Regulatory partnership
> Participate in Health Technology Assessment (HTA) and reimbursement reviews | 100,000 | National | Regularly | 115009387424 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | Cancer
> Cancer: most types | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 10,000 | National | Regularly | 114998266569 |
| Attendance at relevant committee meetings and informal consultative sessions. | Congenital
> Congenital: heart | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 10,000 | National | Rarely | 115003445044 |
| Activities include policy forums, stakeholder consultations, meetings with relevant government ministries, and related engagements. | Rare
> Rare diseases: most types | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 1,000 | National | Regularly | 115033450975 |
| Convening public hearings in the National Assembly and submitting formal recommendations to the Ministry of Health and Welfare [in Korea]. | Mental health
> Mental health: most conditions | Impacting policy and legislation
> Influence healthcare policy and legislation | 5,000 | Regional | Sometimes | 115019561629 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab and the graft-versus-host disease treatment Belumosudil. | Cancer
> Cancer: blood | Impacting policy and legislation
> Participate in public hearings and consultations | 100,000 | Regional | Sometimes | 115008918207 |
| Convening of National Assembly public hearings. | Mental health
> Mental health: most conditions | Impacting policy and legislation
> Participate in public hearings and consultations | 5,000 | Regional | Sometimes | 115019561629 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | Cancer
> Cancer: blood | Impacting policy and legislation
> Participate in public hearings and consultations | 1,000 | Regional | Sometimes | 115028455157 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | Patient advocacy
> Patient rights | Impacting policy and legislation
> Participate in public hearings and consultations | 5,000 | Regional | Regularly | 115033350867 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | Cancer
> Cancer: breast | Impacting policy and legislation
> Participate in public hearings and consultations | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | Neurodegenerative
> Parkinson’s | Impacting policy and legislation
> Addressing barriers/anomalies in medical care | 5,000 | National | Rarely | 115055431165 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | Cancer
> Cancer: most types | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 10,000 | National | Regularly | 114998266569 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | Cancer
> Cancer: breast | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 5,000 | National | Sometimes | 115058944486 |
| We assess cost-effectiveness. | Liver
> Liver diseases: most types | Pricing and affordability advocacy
> Engage in price-review board negotiations | 100,000 | National | Sometimes | 114998327089 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | Cancer
> Cancer: blood | Pricing and affordability advocacy
> Engage in price-review board negotiations | 1,000 | Regional | Sometimes | 115028455157 |
| Reimbursement rates for basic welfare recipients. | Mental health
> Mental health: most conditions | Pricing and affordability advocacy
> Address cost barriers for low-income and vulnerable people | 5,000 | Regional | Sometimes | 115021952415 |
| Inclusion of medical devices — such as continuous glucose monitors and insulin pumps — on the national health insurance formulary. | Endocrine
> Diabetes: type 1 | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 100,000 | National | No | 114998267322 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab [help the body's immune system recognize and destroy cancer] and the graft-versus-host disease treatment Belumosudil. | Cancer
> Cancer: blood | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 100,000 | Regional | Sometimes | 115008918207 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | Cancer
> Cancer: blood | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 1,000 | Regional | Sometimes | 115028455157 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | Cancer
> Cancer: breast | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | Neurodegenerative
> Parkinson’s | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 5,000 | National | Rarely | 115055431165 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | General health
> Healthcare delivery | Evidence-based patient input
> Use patient insights to inform decisions | 100,000 | National | Regularly | 115009387424 |
| We submit written recommendations on a regular basis. | Cancer
> Cancer: blood | Evidence-based patient input
> Use patient insights to inform decisions | 10,000 | National | Regularly | 115056090120 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | Cancer
> Cancer: breast | Evidence-based patient input
> Use patient insights to inform decisions | 5,000 | National | Sometimes | 115058944486 |
| We submit written recommendations on a regular basis. | Cancer
> Cancer: blood | Evidence-based patient input
> Translate evidence and insights into policy input | 10,000 | National | Regularly | 115056090120 |
| Attendance at relevant committee meetings and informal consultative sessions. | Congenital
> Congenital: heart | Institutional governance
> Ensure representation within governmental advisory bodies | 10,000 | National | Rarely | 115003445044 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | General health
> Healthcare delivery | Institutional governance
> Ensure representation within governmental advisory bodies | 100,000 | National | Regularly | 115009387424 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | Patient advocacy
> Patient rights | Upholding patient rights/improving quality of life
> Protecting/improving the patient experience | 5,000 | Regional | Regularly | 115033350867 |
interactions
actions & advocacy
7 mentions
